Tephrosin induces internalization and degradation of EGFR and ErbB2 in HT-29 human colon cancer cells

Cancer Letters

Volumn 293, Issue 1, 2010, Pages 23-30

  Choi, Sujin ^a   Choi, Yunjin ^a   Tien Dat, Nguyen ^b   Hwangbo, Cheol ^a   Lee, Jung Joon ^b   Lee, Jeong Hyung ^a  

^a Kangwon National University   (South Korea)

^b Korea Research Institute of Bioscience and Biotechnology (KRIBB)   (South Korea)

Author keywords

Caspase independent apoptosis; EGFR; Endocytosis; ErbB2; Tephrosin

Indexed keywords

ANTINEOPLASTIC AGENT; APOPTOSIS INDUCING FACTOR; CASPASE 3; CHLOROQUINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; MITOGEN ACTIVATED PROTEIN KINASE 1; NEU DIFFERENTIATION FACTOR; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN KINASE B; TEPHROSIN; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CELL VIABILITY; COLON CANCER; CONTROLLED STUDY; CYTOTOXICITY; ENDOCYTOSIS; ENZYME ACTIVATION; HUMAN; HUMAN CELL; INTERNALIZATION; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; SIGNAL TRANSDUCTION;

APOPTOSIS; BLOTTING, WESTERN; CASPASES; CELL DEATH; CELL GROWTH PROCESSES; CELL LINE, TUMOR; COLONIC NEOPLASMS; EPIDERMAL GROWTH FACTOR; FEMALE; HCT116 CELLS; HT29 CELLS; HUMANS; MALE; NEUREGULIN-1; PHOSPHORYLATION; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; RECEPTOR, ERBB-3; ROTENONE;

EID: 77952419753     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2009.12.012     Document Type: Article

References (37)

1. Riese D.J., Stern D.F. Specificity within the EGF family/ErbB receptor family signaling network. Bioessays 1998, 20:41-48.
2. Yarden Y., Sliwkowski M.X. Untangling the ErbB signalling network. Nat. Rev. Mol. Cell. Biol. 2001, 2:127-137.
3. Olayioye M.A., Neve R.M., Lane H.A., Hynes N.E. The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J. 2000, 19:3159-3167.
4. Lohrisch C., Piccart M. An overview of HER-2. Semin. Oncol. 2001, 28:3-11.
5. Laskin J.J., Sandler A.B. Epidermal growth factor receptor: a promising target in solid tumours. Cancer Treat. Rev. 2004, 30:1-17.
6. Jardines L., Weiss M., Fowble B., Green M. neu (c-erbB-2/HER-2) and the epidermal growth factor receptor (EGFR) in breast cancer. Pathobiology 1993, 61:268-282.
7. Slamon D.J., Godolphin W., Jones L.A., Holt J.A., Wong S.G., Keith D.E., Levin W.J., Stuart S.G., Udove J., Ullrich A., Press M.F. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989, 244:707-712.
8. Allgayer H., Babic R., Gruetzner K.U., Tarabichi A., Schildberg F.W., Heiss M.M. c-erbB-2 is of independent prognostic relevance in gastric cancer and is associated with the expression of tumor-associated protease systems. J. Clin. Oncol. 2000, 18:2201-2209.
9. Ritter C.A., Arteaga C.L. The epidermal growth factor receptor-tyrosine kinase: a promising therapeutic target in solid tumors. Semin. Oncol. 2003, 30:3-11.
10. Grunwald V., Hidalgo M. Developing inhibitors of the epidermal growth factor receptor for cancer treatment. J. Natl. Cancer Inst. 2003, 95:851-867.
11. Paez J.G., Jänne P.A., Lee J.C., Tracy S., Greulich H., Gabriel S., Herman P., Kaye F.J., et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004, 304:1497-1500.
12. Gerhäuser C., Mar W., Lee S.K., Suh N., Luo Y., Kosmeder J., et al. Rotenoids mediate potent cancer chemopreventive activity through transcriptional regulation of ornithine decarboxylase. Nat. Med. 1995, 1:260-266.
13. Fang N., Casida J.E. Anticancer action of cubé insecticide: correlation for rotenoid constituents between inhibition of NADH: ubiquinone oxidoreductase and induced ornithine decarboxylase activities. Proc. Natl. Acad. Sci. USA 1998, 95:3380-3384.
14. Murillo G., Salti G.I., Kosmeder J.W., Pezzuto J.M., Mehta R.G. Deguelin inhibits the growth of colon cancer cells through the induction of apoptosis and cell cycle arrest. Eur. J. Cancer 2002, 38:2446-2454.
15. Hail N., Lotan R. Apoptosis induction by the natural product cancer chemopreventive agent deguelin is mediated through the inhibition of mitochondrial bioenergetics. Apoptosis 2004, 9:437-447.
16. Lee H.Y., Suh Y.A., Kosmeder J.W., Pezzuto J.M., Hong W.K., Kurie J.M. Deguelin-induced inhibition of cyclooxygenase-2 expression in human bronchial epithelial cells. Clin. Cancer Res. 2004, 10:1074-1079.
17. Chun K.H., II Kosmeder J.W., Sun S., Pezzuto J.M., Lotan R., Hong W.K., Lee H.Y. Effects of deguelin on the phosphatidylinositol 3-kinase/Akt pathway and apoptosis in premalignant human bronchial epithelial cells. J. Natl. Cancer Inst. 2003, 95:291-302.
18. Oh S.H., Woo J.K., Yazici Y.D., Myers J.N., Kim W.Y., Jin Q., Hong S.S., Park H.J., Suh Y.G., Kim K.W., Hong W.K., Lee H.Y. Structural basis for depletion of heat shock protein 90 client proteins by deguelin. J. Natl. Cancer Inst. 2007, 99:949-961.
19. Konoshima T., Terada H., Kokumai M., Kozuka M., Tokuda H., Estes J.R., Li L., Wang H.K., Lee K.H. Studies on inhibitors of skin tumor promotion, XII. Rotenoids from Amorpha fruticosa. J. Nat. Prod. 1993, 56:843-848.
20. Wangensteen H., Alamgir M., Rajia S., Samuelsen A.B., Malterud K.E. Rotenoids and isoflavones from Sarcolobus globosus. Planta Med. 2005, 71:754-758.
21. Dat N.T., Lee J.H., Lee K., Hong Y.S., Kim Y.H., Lee J.J. Phenolic constituents of Amorpha fruticosa that inhibit NF-κB activation and related gene expression. J. Nat. Prod. 2008, 71:1696-1700.
22. Matsuda H., Yoshida K., Miyagawa K., Asao Y., Takayama S., Nakashima S., Xu F., Yoshikawa M. Rotenoids and flavonoids with anti-invasion of HT1080, anti-proliferation of U937, and differentiation-inducing activity in HL-60 from Erycibe expansa. Bioorg. Med. Chem. 2007, 15:1539-1546.
23. Lin J.W., Ju W., Foster K., Lee S.H., Ahmadian G., Wyszynski M., Wang Y.T., Sheng M. Distinct molecular mechanisms and divergent endocytotic pathways of AMPA receptor internalization. Nat. Neurosci. 2000, 3:1282-1290.
24. Kitagawa K., Niikura Y. Caspase-independent mitotic death (CIMD). Cell Cycle 2008, 7:1001-1005.
25. Galluzzi L., Joza N., Tasdemir E., Maiuri M.C., Hengartner M., Abrams J.M., Tavernarakis N., Penninger J., Madeo F., Kroemer G. No death without life: vital functions of apoptotic effectors. Cell Death Differ. 2008, 15:1113-1123.
26. Guy P.M., Platko J.V., Cantley L.C., Cerione R.A., Carraway K.L. Insect cell-expressed p180erbB3 possesses an impaired tyrosine kinase activity. Proc. Natl. Acad. Sci. USA 1994, 91:8132-8136.
27. Kim H.H., Vijapurkar U., Hellyer N.J., Bravo D., Koland J.G. Signal transduction by epidermal growth factor and heregulin via the kinase-deficient ErbB3 protein. Biochem. J. 1998, 334:189-195.
28. Holbro T., Beerli R.R., Maurer F., Koziczak M., Barbas C.F., Hynes N.E. The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation. Proc. Natl. Acad. Sci. USA 2003, 100:8933-8938.
29. Massie C., Mills I.G. The developing role of receptors and adaptors. Nat. Rev. Cancer 2006, 6:403-409.
30. Avrov K., Kazlauskas A. The role of c-Src in platelet-derived growth factor-α receptor internalization. Exp. Cell Res. 2003, 291:426-434.
31. Kallal L., Gagnon A.W., Penn R.B., Benovic J.L. Visualization of agonist-induced sequestration and down-regulation of a green fluorescent protein-tagged β2-adrenergic receptor. J. Biol. Chem. 1998, 273:322-328.
32. Jaramillo M.L., Leon Z., Grothe S., Paul-Roc B., Abulrob A., O'Connor McCourt M. Effect of the anti-receptor ligand-blocking 225 monoclonal antibody on EGF receptor endocytosis and sorting. Exp. Cell Res. 2006, 312:2778-2790.
33. Adachi S., Nagao T., To S., Joe A.K., Shimizu M., Matsushima-Nishiwaki R., Kozawa O., Moriwaki H., Maxfield F.R., Weinstein I.B. (-)-Epigallocatechin gallate causes internalization of the epidermal growth factor receptor in human colon cancer cells. Carcinogenesis 2008, 29:1986-1993.
34. Adachi S., Shimizu M., Shirakami Y., Yamauchi J., Natsume H., Matsushima-Nishiwaki R., To S., Weinstein I.B., Moriwaki H., Kozawa O. (-)-Epigallocatechin gallate downregulates EGF receptor via phosphorylation at Ser1046/1047 by p38 MAP kinase in colon cancer cells. Carcinogenesis 2009, 30:1544-1552.
35. Barr D.J., Ostermeyer-Fay A.G., Matundan R.A., Brown D.A. Clathrin-independent endocytosis of ErbB2 in geldanamycin-treated human breast cancer cells. J. Cell Sci. 2008, 121:3155-3166.
36. Zhou Y., Li S., Hu Y.P., Wang J., Hauser J., Conway A.N., Vinci M.A., Humphrey L., Zborowska E., Willson J.K., Brattain M.G. Blockade of EGFR and ErbB2 by the novel dual EGFR and ErbB2 tyrosine kinase inhibitor GW572016 sensitizes human colon carcinoma GEO cells to apoptosis. Cancer Res. 2006, 66:404-411.
37. Zhou Y., Brattain M.G. Synergy of epidermal growth factor receptor kinase inhibitor AG1478 and ErbB2 kinase inhibitor AG879 in human colon carcinoma cells is associated with induction of apoptosis. Cancer Res. 2005, 65:5848-5856.